Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy

Journal of Infectious Diseases

Volumn 211, Issue 5, 2015, Pages 744-754

  Estes, Jacob D ^c   Reilly, Cavan ^b   Trubey, Charles M ^c   Fletcher, Courtney V ^e   Cory, Theodore J ^e   Piatak, Michael ^c   Russ, Samuel ^a   Anderson, Jodi ^a   Reimann, Thomas G ^a   Star, Robert ^d   Smith, Anthony ^b   Tracy, Russell P ^f   Berglund, Anna ^a   Schmidt, Thomas ^a   Coalter, Vicky ^c   Chertova, Elena ^c   Smedley, Jeremy ^c   Haase, Ashley T ^b   Lifson, Jeffrey D ^c   Schacker, Timothy W ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Fibroblastic reticular cell network; Fibrosis; HIV; Immune reconstitution; T cell depletion

Indexed keywords

ANTIRETROVIRUS AGENT; COLLAGEN TYPE 1; D DIMER; DARUNAVIR; DESMIN; EMTRICITABINE; HYALURONIC ACID; INTERLEUKIN 6; L 870812; PIRFENIDONE; RALTEGRAVIR; RITONAVIR; SMAD2 PROTEIN; SMAD3 PROTEIN; TENOFOVIR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CELL STRUCTURE; CELL SURVIVAL; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FIBROSIS; LYMPH TISSUE FIBROSIS; LYMPHOCYTE COUNT; LYMPHOID TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETICULUM CELL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE SUBPOPULATION; TIME TO TREATMENT; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; LYMPH NODE; PATHOLOGY; PROCEDURES; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; LYMPH NODES; MACACA MULATTA; PYRIDONES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 84942305035     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu519     Document Type: Article

References (37)

1. Dummer W, Ernst B, Le Roy E, Lee D, Surh C. Autologous regulation of naive T cell homeostasis within the T cell compartment. J Immunol 2001;166:2460-8.
2. Gretz JE, Anderson AO, Shaw S. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol Rev 1997;156:11-24.
3. Kaldjian EP, Gretz JE, Anderson AO, Shi Y, Shaw S. Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membrane-like extracellular matrix. Int Immunol 2001;13:1243-53.
4. Kataki T, Shimizu A. The network of fibroblastic reticular cells in the lymph node: functional framework for immune surveillance. Curr Immunol Rev 2007;3:251-7.
5. Von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003;3:867-78.
6. Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001;167:6869-76.
7. Bajenoff M, Egen JG, Koo LY, et al. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006;25:989-1001.
8. Tan JT, Dudl E, Le Roy E, et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci USA 2001;98:8732-7.
9. Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J Exp Med 2000;192:1425-40.
10. Sixt M, Kanazawa N, Selg M, et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 2005;22:19-29.
11. Estes JD, Li Q, Reynolds MR, et al. Premature induction of an immu-nosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis 2006;193:703-12.
12. Estes JD, Wietgrefe S, Schacker T, et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007;195:551-61.
13. Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lym-phoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011;121:998-1008.
14. Estes JD, Haase AT, Schacker TW. The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Semin Immunol 2008;20:181-6.
15. Schacker TW, Brenchley JM, Beilman GJ, et al. Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006;13:556-60.
16. Schacker TW, Nguyen PL, Beilman GJ, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002;110:1133-9.
17. Schacker TW, Reilly C, Beilman GJ, et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 2005;19:2169-71.
18. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998;83:219-23.
19. Dosanjh A, Ikonen T, Wan B, Morris RE. Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther 2002;15:433-7.
20. Giri SN, Wang Q, Xie Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002;23:203-11.
21. Brook NR, Waller JR, Bicknell GR, Nicholson ML. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of ta-crolimus-induced nephrotoxicity. J Surg Res 2005;125:137-43.
22. Garcia L, Hernandez I, Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002;37:797-805.
23. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-94.
24. Negri AL. Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents. J Nephrol 2004;17:496-503.
25. Tian XL, Yao W, Guo ZJ, Gu L, Zhu YJ. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metallopro-teinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin Med Sci J 2006;21:145-51.
26. Zhao XY, Zeng X, Li XM, Wang TL, Wang BE. Pirfenidone effectively inhibits carbon tetrachloride- and albumin complex-induced liver fibro-sis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol 2009;36:963-8.
27. ∗08-positive macaques control simian immunodeficiency virus replication. J Virol 2007;81:8827-32.
28. O'Connor DH, Mothe BR, Weinfurter JT, et al. Major histocompatibil-ity complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol 2003;77:9029-40.
29. Cline AN, Bess JW, Piatak M Jr, Lifson JD. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 2005;34:303-12.
30. Estes J, Baker JV, Brenchley JM, et al. Collagen deposition limits immune reconstitution in the gut. J Infect Dis 2008;198:456-64.
31. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis 2011;203:1637-46.
32. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-36.
33. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfe-nidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1 (I), TIMP-1 and MMP-2. Dig Liver Dis 2004;36:744-51.
34. Kaibori M, Yanagida H, Uchida Y, et al. Pirfenidone protects endotox-in-induced liver injury after hepatic ischemia in rats. Transplant Proc 2004;36:1973-4.
35. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998;54:99-109.
36. Zhang S, Shiels IA, Ambler JS, Taylor SM. Pirfenidone reduces fibronec-tin synthesis by cultured human retinal pigment epithelial cells. Aust NZJ Ophthalmol 1998;26(suppl 1):S74-6.
37. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009;22:279-85.